[Newsmp] As pharmaceutical and bio companies continue to underperform, the market capitalization of the pharmaceutical index is experiencing a significant decline, jeopardizing the KRW 100 trillion mark.
According to the Korea Exchange, the combined market capitalization of the 47 constituent stocks (excluding preferred stocks) in the pharmaceutical index of the KOSPI market decreased by KRW 6.7588 trillion in June, reaching KRW 106.588 trillion.
Within this timeframe, among the 47 constituent stocks, 12 stocks suffered a decline of over 10% in their share prices, and more than half of them dropped by more than 5%.
Il Dong Holdings saw the highest decline of 24.2%, while Gene One Life Science recorded a drop of 22.0%, surpassing a decline of 20%.
Il Dong Pharmaceutical decreased by 18.9%, Pharmicell by 16.0%, Daewoong by 14.6%, Hyundai Pharmaceutical by 13.8%, BioNote by 13.3%, Daewoong Pharmaceutical by 12.9%, Yungjin Pharm. by 12.0%, Yuyu Pharma by 11.7%, Samsung Pharmaceutical by 11.0%, and Celltrion by 10.7%.
Furthermore, the share prices of Green Cross, CKD Bio, Whanin Pharmaceutical, Myungmoon Pharmaceutical, Boryung Pharmaceutical, Bukwang Pharmaceutical, Chong Kun Dang Pharmaceutical, Reyon Pharmaceutical, HanAll Biopharma, Handok, Aprogen Pharmaceuticals, Shin Poong Pharmaceutical, and Samsung Biologics experienced a drop of more than 5%.
Compared to the end of the previous month, Jeil Pharmaceutical, SK Bioscience, PharmGen Science, Kyongbo Pharmaceutical, Kukje Pharma, Hana Pharm, Chong Kun Dang Holdings, Ilsung Pharmaceutical, Il-Yang Pharmaceutical, Samjin Pharmaceutical, and Daewon Pharmaceutical declined in their share prices.
On the other hand, there was no stock that recorded a double-digit increase rate. Samil Pharmaceutical showed the highest increase with 9.6%, followed by JW Life Science with 8.5%, Dong Wha Pharm with 8.2%, Korea United Pharm. with 6.0%, and Hanmi Pharmaceutical with 5.5%, totaling 5 stocks that saw a share price increase of over 5%.
In addition, Dong-A ST, ORIENTBIO, Dongsung Pharmaceutical, Kwang Dong Pharmaceutical, Yuhan Corporation, and JW Pharmaceutical, also increase slightly in their stock prices compared to the end of May.
In terms of market capitalization, Samsung Biologics decreased by KRW 2.847 trillion, and Celltrion by KRW 2.926 trillion. SK Bioscience, Daewoong Pharmaceutical, Green Cross, and Daewoong also saw their market capitalization shrink by over KRW 100 billion.
Meanwhile, Hanmi Pharmaceutical was the only stock that experienced an increase in market capitalization of over KRW 100 billion.
As of the end of June, Samsung Biologics had the largest market capitalization of KRW 52.9535 trillion, followed by KRW Celltrion at 22.3832 trillion.
SK Bioscience followed with a market capitalization of KRW 6.1043 trillion, Yuhan Corporation with KRW 4.629 trillion, and Hanmi Pharmaceutical with KRW 3.8753 trillion while Green Cross, Daewoong Pharmaceutical, HanAll Biopharma, and Chong Kun Dang Pharmaceutical maintained market capitalization in the trillion-won range.
